Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

NCT05182476 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

216

Enrollment

INDUSTRY

Sponsor class

Stopped Failed to meet the primary endpoint

Conditions

Schizophrenia

Interventions

DRUG: Placebo
DRUG: Luvadaxistat

Sponsor

Neurocrine Biosciences